CoChat

Glucagon‐like peptide‐1 analogue therapy for psoriasis patients with obesity and type 2 diabetes: a prospective cohort study

Ahern, T., Tobin, A.‐M., Corrigan, M., Hogan, A., Sweeney, C., Kirby, B., O’Shea, D. · 2013 · Journal of the European Academy of Dermatology and Venereology
Cited by 90

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

Background Diabetes and obesity are more prevalent amongst psoriasis patients as is disturbance of the innate immune system. GLP‐1 analogue therapy considerably improves weight and glycaemic control in people with type 2 diabetes and its receptor is present on innate immune cells. Objective We aimed to determine the effect of liraglutide, a GLP‐1 analogue, on psoriasis severity. Methods Before and after 10 weeks of liraglutide therapy (1.2 mg subcutaneously daily) we determined the psoriasis area and severity index (PASI) and the dermatology life quality index (DLQI) in seven people with both psoriasis and diabetes (median age 48 years, median body mass index 48.2 kg/m 2). We also evaluated the immunomodulatory properties of liraglutide by measuring circulating lymphocyte subset numbers and monocyte cytokine production. Results Liraglutide therapy decreased the median PASI from 4.8 to 3.0 (P = 0.03) and the median DLQI from 6.0 to 2.0 (P = 0.03). Weight and glycaemic control improved significantly. Circulating invariant natural killer T (iNKT) cells increased from 0.13% of T lymphocytes to 0.40% (P = 0.03). Liraglutide therapy also effected a non‐significant 54% decrease in the proportion of circulating monocytes that produced tumour necrosis factor alpha (P = 0.07). Conclusion GLP‐1 analogue therapy improves psoriasis severity, increases circulating iNKT cell number and modulates monocyte cytokine secretion. These effects may result from improvements in weight and glycaemic control as well as from direct immune effects of GLP‐1 receptor activation. Prospective controlled trials of GLP‐1 therapies are warranted, across all weight groups, in psoriasis patients with and without type 2 diabetes.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1468-3083.2012.04609.x

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 90

Metadata

Authors
Ahern, T., Tobin, A. ‐., Corrigan, M., Hogan, A., Sweeney, C., Kirby, B., & O’Shea, D.
Venue
Journal of the European Academy of Dermatology and Venereology
Publisher
Wiley
Published
2012-06-13
Volume
27
Issue
11
Pages
1440-1443
ISSN
  • 0926-9959 (ISSN-L)
  • 1468-3083
OpenAlex
W1896914803
Cited by
90
References
3
FWCI
2.10
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Glucagon‐like peptide‐1 analogue therapy for psoriasis patients with obesity and type 2 diabetes: a prospective cohort study. https://app.cochat.ai/papers/10.1111/j.1468-3083.2012.04609.x
The paper
Ahern, T., Tobin, A. ‐., Corrigan, M., Hogan, A., Sweeney, C., Kirby, B., & O’Shea, D. (2013). Glucagon‐like peptide‐1 analogue therapy for psoriasis patients with obesity and type 2 diabetes: a prospective cohort study. Journal of the European Academy of Dermatology and Venereology. https://doi.org/10.1111/j.1468-3083.2012.04609.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.